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Inherent to anorexia nervosa and bulimia nervosa are a plethora of medical complications which correlate with the
severity of weight loss or the frequency and mode of purging. Yet, the encouraging fact is that most of these medical
complications are treatable and reversible with definitive care and cessation of the eating-disordered behaviours.
Herein, these treatments are described for both the medical complications of anorexia nervosa and those which are
a result of bulimia nervosa.
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As opposed to most other psychiatric disorders where
there may be no medical complications associated with
those illnesses, anorexia nervosa and bulimia nervosa
inherently have many different medical complications.
The specific treatments for those associated with anorexia
nervosa and bulimia nervosa are described below.
Anorexia nervosa
Treatment of secondary amenorrhoea and infertility
Secondary amenorrhea is a hallmark of anorexia nervosa.
Although no longer considered a diagnostic criterion, it is
nevertheless a nearly ubiquitous feature of severe weight
loss and can often be a presenting feature of the disease
[1,2]. The development of amenorrhea is most strongly
correlated to loss of body weight. There is variability in
the literature regarding the degree of weight restoration
needed for resumption of menses, with some sources
citing return to ninety percent of ideal body weight, and
others seeing a stronger correlation with the weight at
which cessation of menses was observed [3,4].
Although weight restoration is the mainstay of treatment
for amenorrhea in the setting of anorexia nervosa,
there has been some investigation into pharmacologic
intervention targeted at the disrupted hypothalamic-gonadal
axis. Leptin is a hormone that is secreted by adipocytes and* Correspondence: PMehler@dhha.org
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unless otherwise stated.functions as a mediator in the adaptation to energy
deprivation. Women with hypothalamic amenorrhea have
been shown to have low leptin levels compared to
matched controls [5,6]. Two studies have demonstrated
that administration of recombinant leptin can restore func-
tion of the hypothalamic-gonadal axis, with the resumption
of menses [7,8]. However, these studies were performed in
subjects, who despite having hypothalamic amenorrhea,
had weights which were only in the low-normal range, and
therefore the results have limited applicability to the overall
anorexia nervosa population.
Therefore given the generally reliable resumption of
menses with weight restoration, it would seem that there
is generally little role for a pharmacologic intervention
to achieve this effect sooner. Hence, it is, once again,
inadvisable to use oral contraceptives in this setting
singularly for the purpose of inducing a withdrawal
bleeding for patients with anorexia nervosa. There has
been essentially no clinical benefit demonstrated for
estrogen replacement in this population [9]. Moreover,
induction of withdrawal bleeding can give a false
sense of wellness to these patients which potentially can
temper motivation for ongoing necessary nutritional
rehabilitation and weight restoration.
Despite lack of menses, it is possible for women with
anorexia nervosa to become pregnant, and therefore it
should not be assumed that contraception is unnecessary
in these patients [10]. However, women with a history
of anorexia are more likely to have future problems
with fertility, and are more likely to have persistentThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to the general population [11]. Women with a history of
anorexia nervosa who do become pregnant are at greater
risk for pregnancy complications such as hyperemesis
gravidum, and spontaneous abortion, as well as adverse
neonatal outcomes such as low birth weight [12,13]. Given
the lack of clear correlation between features of anorexia
nervosa and subsequent pregnancy complications, there is
no clear treatment or preventative measure for this issue,
other than treatment of the underlying eating disorder
and nutritional deficiencies.
Treatment of bone disease
Decrease in bone mineral density is commonly found in
anorexia nervosa. Therefore, it is estimated that patients
with anorexia nervosa are three times more likely to
have a fracture, compared with the general population
[14]. The degree of bone loss has been correlated both
with body mass index and duration of amenorrhea [15].
Contrary to the bone mineral density loss observed in
post-menopausal women, bone loss in anorexia nervosa
seems to be driven by a multifactorial process beyond just
low estrogen, including hypercortisolemia, and reduced
levels of androgens, leptin and insulin-like growth factor 1
(IGF-1). While the mainstay of treatment for bone density
loss is weight gain and restoration of menstrual function,
data have shown that decreased bone density may persist
long after weight has again reached a normal level
[16]. Based on this observation, efforts have been made to
identify an adjuvant pharmacological therapy that could
aid in bone density restoration, given its often early age of
onset and long-term increased fracture risk.
Consideration has been given to the role of estrogen
replacement therapy to target one of the many mecha-
nisms leading to bone loss. However, there are little
compelling data supporting this heretofore accepted prac-
tice. Additionally, as noted above, there exists concern that
the use of estrogen in this setting, generally in the form of
oral contraceptive pills, can in fact have deleterious effects
by giving a false sense of normalcy [9]. There should
actually be high reluctance to use it for this indication
alone. Yet there is evidence of a lack of knowledge about
this recommendation and many physicians continue
to inappropriately prescribe estrogen therapy in anorexia
nervosa [17]. While there exits one randomized controlled
trial of 60 women with anorexia nervosa, that did show a
statistically significant increase in bone density following
treatment with oral contraceptive pills when coupled
with recombinant human IGF-1 [18], further compelling
data on this effect are lacking. In addition no clinical role
has yet been adopted for IGF-1 in patients with anorexia
nervosa.
Bisphosphonates have also been investigated as a possible
treatment modality to increase bone density, given theirsuccessful use in post-menopausal women. However, due
to the teratogenic nature of these drugs there is some
concern about their use in women of childbearing
age. It is known that bisphosphonates can remain in
the body for many years after discontinuation, therefore
raising concern for adverse effects on fetal development
during pregnancies even years in the future. There are
little data available about the outcomes of children
born to mothers previously treated with these medica-
tions. Additionally, the data to support the efficacy of
these medications in the anorexia nervosa population are
somewhat limited. The most compelling study exploring
this issue is a 2005 trial by Golden et al. in which 32
adolescents with anorexia nervosa were randomized
to receive either alendronate or placebo. At one-year
follow up, there was an increase in bone mineral density
in both groups, correlated most closely with weight gain.
The increase was greater in the alendronate group, but
not significantly so compared with placebo [19]. There
may be justification for their use in patients with severe
osteoporosis and for males with normal testosterone
levels. If the serum testosterone level is however low, then
testosterone injection or patch therapy until the level
returns to normal is reasonable [20].
Additional agents that have been considered as potential
stimulants for bone formation and mineralization include,
calcitonin, raloxifene, and testosterone, but none have
been shown to have reliable effects in female patients with
anorexia nervosa. There is one very recent study using
teriparatide which showed substantial improvement in
bone density after just six months of therapy in women
with anorexia nervosa [21]. Calcium (1200 mg/day) and
vitamin D (800 IU/day) are necessary for bone growth and
development; however calcium supplementation is not
sufficient by itself to prevent osteopenia in the setting
of severe weight loss, nor is it effective treatment for
decreased bone density once it exists [22].
Unlike most other medical complications of anorexia
nervosa, bone density loss may not be fully reversible
even with restoration to a normal weight. This is one of
the few complications wherein the adverse effects may
persist long-term, and arguably this may be one of greatest
concern given their increased long-term fracture risk.
Further studies to more fully explore the use of medica-
tions, validate the degree of associated risk, and investigate
new agents will be necessary to provide more effective
treatment.
Finally, some of the complications of anorexia nervosa
do not require primary treatment once diagnosed beyond
thoughtful reassurance for the patient and perhaps using
the objective medical complication as leverage to try to
exhort them to push on with nutritional rehabilitation and
weight restoration. These include acrocyanosis, lanugo hair
growth and the anemia, leukopenia and thrombocytopenia
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Treatment of cardiovascular complications
The primary cardiovascular complications of eating
disorders include hemodynamic, conduction system, and
structural heart alterations. Among the most common
alterations is orthostatic or relative hypotension even
among ambulatory populations [23]. In general treatment
of more significant hypotension can be accomplished with
intravenous fluids among inpatients particularly if symp-
tomatic, though hypotension improves with restoration of
body mass. Hypotension may also accompany bradycardia
making postural symptoms more pronounced.
Bradycardia is among the most common cardiac com-
plications of anorexia nervosa, but absent high-grade
atrioventricular block rarely requires cardiac subspecialist
consultation. In rare cases, persistent junctional rhythm
may be present in patients with severe anorexia nervosa.
This may delay transitions of care from inpatient to
outpatient treatment facilities and may lead to prolonged
telemetry monitoring and increased hospital length of
stay. In this case, we suggest provocative treadmill testing
to demonstrate appropriate conversion to sinus rhythm in
these patients as a means to assess cardiac electrical
reserve [24]. Another common cardiac complication
involving the electrical system is QTc interval pro-
longation, which has been postulated to underly the
high risk of sudden cardiac death. However, even in
patients with severe anorexia nervosa, marked QTc
interval prolongation is uncommon when contributing fac-
tors such as hypokalemia are not present [25]. Expectant
management of QTc prolongation is generally adequate
including serial electrocardiography and telemetry moni-
toring in conjunction with electrolyte (potassium and
magnesium) repletion and discontinuation of drugs known
to prolong the QTc interval (including anti-emetics and
antipsychotics). Patients with eating disorders also exhibit
alterations in autonomic function and heart rate variability
[26], though the clinical implications of these abnormalities
are uncertain.
Another important issue in patients with restricting
eating disorders is alteration in cardiac structure. Most
commonly reductions in left ventricular mass are seen
during starvation, but this is generally reversible. Some
patients will develop pericardial effusions, which are
generally self-limited and resolve with weight restoration.
Pericardiocentesis is reserved solely for patients with
evidence of cardiac tamponade by echocardiographic
and/or clinical criteria. Recently, myocardial fibrosis
(detected as late gadolinium enhancement on magnetic
resonance imaging) was found in 23% of patients with
anorexia nervosa [27]. This finding indicates the possibil-
ity of scar tissue and could theoretically underly apropensity to sudden cardiac death. Whether theses struc-
tural changes are reversible or etiologic with regard to
arrhythmogenesis remain to be determined. Finally, mitral
valve prolapse in association with the aforementioned left
ventricular atrophy is very common due to changes in the
valve annulus. However, even in the setting of mitral
insufficiency, treatment remains expectant with serial
echocardiography to document resolution. Overall, the
cardiac complications of eating disorders although
critical to recognize, are often reversible after supervised
weight restoration.
Treatment of gastrointestinal complications
There are multiple gastrointestinal complications due to
anorexia nervosa. Delayed gastric emptying is one of the
most universal of these issues [28]. This condition is
particularly problematic in that the symptoms it causes,
postprandial fullness, bloating, and pain, further perpetu-
ate the patient’s desire to avoid food. Definitive treatment
is weight restoration which has been shown to improve
both gastric emptying and associated symptoms [29]. Diet
modification can serve as effective and sufficient treatment
for some patients [30]. Dividing daily calories in to smaller
meals eaten throughout the day, using liquid supplements
and calorie-dense foods, avoidance of excessive fiber and
perhaps small-particle food sized feeds can help mitigate
some of the symptoms of gastroparesis.
However, for many patients symptoms are sufficiently
problematic that they interfere significantly with weight
restoration, and for these patients promotility agents can
be considered. Metoclopramide, a dopamine receptor
antagonist, has been found to be highly effective, even in
small doses (2.5 mg), to hasten gastric emptying and
reduce troubling symptoms of early satiety which
interferes with nutritional rehabilitation. Appreciable
symptom reduction can be seen with the first dose.
Concern exists with the use of metoclopramide and
the development of tardive dyskinesia. However, data
are lacking regarding the risk of this effect specifically
in the anorexia nervosa population, which tends to use
very small doses of this medication (2.5 mg before meals)
for limited periods of time. A meta-analysis suggests that
the prevalence of this effect in the general population
is in fact less than1%, a number that is significantly
lower than the 1-10% risk quoted in national guidelines
[31]. Other promotility agents sometimes considered for
gastroparesis treatment include erythromycin and dom-
peridone. However, data on these agents in this population
are also lacking, and concerns regarding both safety and
efficacy seem to relegate them to second choices after
metoclopramide [32,33].
Superior mesenteric artery (SMA) syndrome is a rare
etiology of abdominal pain and vomiting in patients with
anorexia nervosa. It is caused by compression of the
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due to loss of the intervening mesenteric fat pad. In the
majority of cases, profound weight loss is responsible for
this anatomic phenomenon. Like gastroparesis, SMA
syndrome is a serious complication of anorexia nervosa as
the obstructive symptoms further exacerbate difficulties in
achieving adequate caloric intake. The mainstay of treat-
ment for SMA syndrome in anorexia nervosa is nutritional
support, to restore the mesenteric fat pad and alleviate the
obstruction. Enteral feeding, either with an oral liquid diet
that can transverse the obstruction, or with a feeding tube
placed into the jejunum, distal to the point of obstruction
are effective short-term interventions [34]. There are case
studies supporting the use of total parenteral nutrition
(TPN) for short durations in cases of SMA syndrome
refractory to enteral feeding, but the risks of parenteral
nutrition must be very carefully considered in this vulner-
able population [35]. The dysphagia and risk of aspiration
seen in the more severely underweight patients with
anorexia nervosa should be treated by well-informed
speech therapists who are familiar with this issue in
anorexia nervosa. Specialized diets, swallowing exercises
and the temporary use of a stimulator applied to the
throat area by these professionals, will, along with good
nutrition, resolve their swallowing challenges [36].
Complaints of constipation frequently accompany
weight loss in anorexia nervosa. This is a complex issue,
as concerns regarding inadequacy of stool frequency and
quantity are often highly influenced by the perception of
what bowel habits the patient believes to be “normal”
and also for desire perhaps from laxatives which the
patient may believe reduce calorie absorption. However,
due to decreased caloric intake and decreased motility of
the gastrointestinal (GI) tract, slowed GI transit times
and reflex hypofunction of the colon are real phenomena
in anorexia nervosa [37]. With weight restoration colonic
motility improves, but dietary modifications and medical
therapy are often needed to treat and prevent progressive
constipation and discomfort during that period of
nutritional rehabilitation. Ensuring adequate fluid intake
can often aid in symptom relief. Stimulant laxatives are
not recommended, as not only can they also cause painful
cramping but long-term, they can cause damage to co-
lonic nerve cells. The preferred treatment modalities are
osmotic laxatives, such as polyethylene glycol powder and
lactulose, dosed based on the frequency of defecation [38].
Additional gastrointestinal problems that are seen in
the context of anorexia nervosa and severe malnutrition
include hepatitis and, rarely, pancreatitis. Markedly elevated
transaminases, are often seen in the context of starvation.
Case reports exist regarding recurrent idiopathic pancrea-
titis in eating disorder patients [39]. Both of these issues
require supportive care in the acute phase. Rarely, elevation
in liver function tests can be related to glucose and fatdeposition during refeeding, which is termed steatosis,
requiring a decrease in caloric advancement or a reduction
in the amount of carbohydrate calories. An ultrasound can
help distinguish between malnutrition induced elevations
and those due to steatosis and can help avoid unnecessary
slowing of refeeding – a modification that is only necessary




For patients with bulimia nervosa, treatment of their
acid reflux symptoms follows the usual treatment plan
generally used for any patient with this disorder, namely
proton pump inhibitors, head of bed elevation and
minimizing oral intake within a few hours of going to
sleep. Although there are no data to suggest that patients
with bulimia nervosa, who purge via self-induced vomiting,
are at increased risk of esophageal carcinoma, good
practice would be to refer a bulimic patient for upper
endoscopy, if their acid reflux is refractory to standard
therapy or anyone with dysphagia or a history of recurrent
hematemesis; this is to exclude Barrett’s esophagus or
even worse, neoplastic changes. Barrett’s remains a risk
factor for esophageal carcinoma and endoscopic surveil-
lance is recommended [41]. In addition, treatment of the
dental consequences of self-induced vomiting largely
revolves around ensuring good dental hygiene to reduce
the harmful effects of stomach acid on teeth enamel.
Brushing lightly with a fluoride-based toothpaste soon after
vomiting is the current practice. Also, the sialadenosis
which can often develop with abrupt cessation of self-
induced vomiting, is treated with sialagogues such as tart
candies, warm packs applied to the sides of the face
multiple times per day and low dose anti-inflammatory
agents such as ibuprofen. For refractory cases, a trial of
prescription pilocarpine (sialogen) should be initiated
before consideration of surgical treatments [42].
For those patients with bulimia nervosa who purge via
stimulant laxative abuse, the treatment challenge which
evolves is how to successfully “detox” them before they
develop the cathartic colon syndrome, wherein their colon
is relegated to an inert tube incapable of propagating fecal
material resulting in severe constipation. There are no
randomized controlled studies to inform how to optimally
achieve cessation of stimulant laxative abuse while
maintaining some degree of normal colonic function.
Nor are there any data which speak to what amount
of stimulant laxative usage is dangerous or over what
duration of usage. Therefore a prudent approach seems to
be one wherein the message delivered to these patients
must be to completely abandon their usage versus simply
reducing the number of stimulant laxatives used each day.
Additionally, adequate fluid intake should be encouraged
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as polyethylene glycol, to obligate intraluminal colonic
absorption of water to assist with soft stools and suc-
cessful defecation, even if that is not on a daily basis.
Using the osmotic laxative, three to four times per day
may be needed for those patients with a long history of
daily stimulant laxative abuse.
Erythromycin in a dose of 250 mg two to three times
per day, may be of utility to stimulate colonic transit,
analogous to its usage in diabetic gastroparesis and other
conditions where slow gastrointestinal transit occurs [43].
Medications such as Lubiprostone, which is approved for
usage in patients with constipation-predominant irritable
bowel syndrome, has never been rigorously studied in
patients with bulimia nervosa who are attempting to
discontinue their stimulant laxative abuse behaviors.
Fluid and electrolyte abnormalities
As mentioned in part two of this series, all modes of
purging, which are engaged in excessively, will result in
hypokalemia and metabolic alkalosis, although milder
cases of diarrhea from laxative abuse, will cause a non-
anion gap acidosis [44]. The mainstays of treatment for
the hypokalemic metabolic alkalosis due to vomiting and
diuretic abuse are intravenous saline and potassium.
However, the efficacy of potassium repletion will be
abrogated unless there is concomitant attention to
correcting the hypovolemia via saline and reducing
aldosterone secretion. Otherwise, urinary losses of potas-
sium continue in response to elevated aldosterone levels.
The key message to be aware of with the usage of intra-
venous saline is that it must be given at a slower than the
typical rate used for dehydrated patients because these
patients are in a strongly salt-avid state and can quickly
put on 5–10 kilograms of edema fluid over the course of
just a few hours; a result that is especially distressing to a
patient population which is consumed by body image
concerns. A prudent approach may be to admit such a
patient to 24 hours observation and to run the intraven-
ous saline at only 50-75 cc/hour for 24–36 hours [45].
Once the serum bicarbonate level normalizes into a range
less than 30mmole/ml, it is safe to discontinue the intra-
venous saline. There are published guidelines as to when
oral potassium repletion suffices and when the intraven-
ous route is preferred [46]. In general for every 1 meq that
the serum potassium level is less than 4.5 meq/L, the
patient is estimated to have lost 100 meq of potassium.
Thus, a critically low value of 2.5 meq/ml would suggest
that there is a deficit of about 200 meq of potassium,
assuming normal kidney function.
Importantly, for those patients with bulimia nervosa,
who decide to abruptly cease their purging behaviors of
either self-induced vomiting or laxative and diuretic abuse,
pseudo-Bartter’s syndrome-induced edema formation canresult in development of marked edema and exuberant
weight gain over just a few days. Expectant proactive edu-
cation must be offered that this risk exists so that these
patients do not quickly revert back to their purging behav-
iors in order to mitigate against rapid and progressive
weight gain. In addition, experienced clinicians typically
prescribe spironolactone, once daily, in a dosage of 25 mg
up to a rarely needed maximum dose of 200 mg, during
the two to three weeks, after abrupt cessation of excessive
and chronic purging behaviors, in order to block aldoster-
one and negate the propensity towards distressing edema
formation and excessive weight gain [47].
Heretofore, low sodium diets have been incorporated
into the treatment program for bulimia nervosa patients
with this aforementioned propensity toward edema
formation. This is similar to congestive heart failure
patients where this measure has also been recommended
despite a clear evidence base for its therapeutic effect.
Recently, this has begun to be challenged as having
no beneficial effect on weight loss or chemical stability in
acute decompensated heart failure patients [48]. Presum-
ably, the potential lack of efficacy may be due to salt re-
striction causing increased aldosterone secretion and
perpetuating the underlying propensity towards edema
formation that was being attended to with the usage of
spironolactone. Indeed, there is emerging evidence that
dietary salt restriction may activate mineralocorticoid
receptor signalling and thus frustrate the efforts to
successfully “detox” these patients with bulimia nervosa
[49]. Thus, it may be prudent to relax the typical two gram
sodium restriction-diet in this population of patients who
are proceeding through the early stages of the absence of
historical purging behaviors.
Readers may note that much of this section on fluid
and electrolytes is also relevant to anorexia nervosa pur-
ging type and purging disorder.
Conclusions
There are effective treatments for the medical complica-
tions of both anorexia nervosa and bulimia nervosa. With
early recognition and appropriate medical treatment,
patient with anorexia nervosa and bulimia nervosa may
achieve successful treatment outcomes.
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